The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...

The outgoing chief executive of Novo Nordisk has revealed plans to ramp-up cost cutting 'efficiencies' across the business, ...

Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 ...

The maker of Ozempic and Wegovy obesity drugs said some of the prices could come down, as President Trump called for ...

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...

As of 2024, Brazil's Semaglutide market was estimated at $581 million. The global market size for the GLP-1 (glucagon-like ...

Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...

Levi & Korsinsky is representing the shareholder plaintiff in a suit claiming the Ozempic and Wegovy manufacturer withheld ...

The diabetes drugs Ozempic and Wegovy have been linked to an increased risk of sudden vision loss and blindness due to a rare eye condition known as ...

Novo Nordisk stock slumped Wednesday after saying it expects compounded versions to undercut sales of its obesity drug, ...